Morgan Stanley analyst Patrick Wood resumed coverage of Edwards Lifesciences with an Equal Weight rating and $70 price target Edwards is “a great business, with an exceptional balance sheet,” and it stands to benefit from TCT catalysts, says the firm, which adds that it is “bullish on TMTT.” However, with slower TAVR growth appreciated by investors, the analyst thinks “shares are priced just right.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences call volume above normal and directionally bullish
- Edwards Lifesciences price target lowered to $75 from $85 at RBC Capital
- Edwards Lifesciences price target lowered to $66 from $77 at Canaccord
- Edwards Lifesciences price target lowered to $70 from $76 at Evercore ISI
- Edwards Lifesciences price target lowered to $77 from $83 at Citi